🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05617846
Starting soon Observational

Application of Antiosteoporosis Therapy in Osteolysis

NCT05617846 · tracked via the Priya Life Science China tracker
Sponsor
Henan Cancer Hospital
Phase
Observational
Started
2024-12-28
Last updated
2024-01-18

Condition(s) studied

Limb; FusionComplication

Investigational drug(s) / intervention(s)

Anti-osteoporosis therapy

Anti-osteoporosis therapy: Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.

Study summary

To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: 1. No age restriction, male or female. 2. A subtype of bone tumor (including benign, malignant, and metastatic cancer) was confirmed in the pathology department of the research institution. 3. Received excision of bone tumor in research institution. Exclusion Criteria: Not applicable.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Bone and Soft Tissue ,Henan Cancer Hospital Zhengzhou Henan

More Henan Cancer Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05617846 on ClinicalTrials.gov ↗ ← All trials in China